Search Clinical Trials

85 Results

Active, Not Recruiting
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (External Link)
To prepare the T cells (GD2-C7R T cells), research staff will take some blood from the patient. We will grow the GD2.C7R T cells by infecting the T cells with …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Patch vs. No Patch Fetoscopic Meningomyelocele Repair Study (External Link)
Spina bifida can be a devastating neurological congenital anomaly. It results from incomplete closure of the neural tube between 22 and 28 embryological days. Its incidence is approximately 1-2 per …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (External Link)
Approximately 18-30 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Effect of Early Range of Motion Following First Time Patellar Dislocation (External Link)
This study will look at two different ways to treat teen-age patients who have had a dislocation of their knee cap. Both groups will receive the physical therapy treatment for …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Measuring and Improving the Safety of Test Result Follow-Up (External Link)
The goal of this study is to develop and evaluate a new program for surveillance and improvement of test results-related diagnostic safety. The investigators will use a multifaceted measurement approach, …
Baylor Role: Collaborator
Active, Not Recruiting
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) (External Link)
Standard cytotoxic chemotherapy is based on the Medical Research Council (MRC) backbone of cytarabine, and daunorubicin. This combination of chemotherapy is highly myelosuppressive and can lead to oral aversions, dietary …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Harms of Hepatocellular Carcinoma Surveillance (External Link)
Leveraging a multi-center randomized controlled trial assessing screening benefits in a socioeconomically and racially diverse population of patients with cirrhosis followed in 3 healthcare settings over a 4-year period, this …
Baylor Role: Collaborator
Active, Not Recruiting
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (External Link)
Double blind, randomized, controlled, Phase 2 clinical trial in hookworm-unexposed adults living in the metropolitan area of Washington, DC. Subjects will receive three doses of the assigned vaccine formulation, or …
Baylor Role: Lead Sponsor
Active, Not Recruiting
TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (External Link)
Status - CLOSED TO PATIENT ENROLLMENT (CNPE) The patient will give blood to make TAA-Specific cytotoxic T cells in a lab. These cells well be grown and frozen. If the …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Oral Care in Infants With Gastroschisis (External Link)
Breast milk is recommended for most infants by the American Academy of Pediatrics as there are multiple benefits. However, some infants, such as extremely premature infants, are unable to receive …
Baylor Role: Lead Sponsor